PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.72% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-03-31
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.58%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-09-30 was 2.93%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-06-30 was 2.93%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 1.46%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.72%, a 0.00% change from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.72%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2013 was 1.26%, a 34.04% increase from fiscal 2012.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2012 was 0.94%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.72% 10-K · filed 2025-03-31 | |||
| 2023-12-31 | 4.72% 10-K · filed 2024-04-01 | |||
| 2019-03-31 | 2.58% 10-Q · filed 2019-05-14 | |||
| 2018-09-30 | 2.93% 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | 2.93% 10-Q · filed 2018-08-14 | |||
| 2016-09-30 | 1.46% 10-Q · filed 2016-11-10 | |||
| 2014-09-30 | 2.52% 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | 1.85% 10-Q · filed 2014-08-14 | 1.91% 10-Q · filed 2014-08-14 | ||
| 2014-03-31 | 2.96% 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | 1.26% 10-K · filed 2014-03-28 | |||
| 2013-09-30 | 1.75% 10-Q · filed 2014-11-13 | 1.26% 10-Q · filed 2013-11-14 | ||
| 2013-06-30 | 1.25% 10-Q · filed 2014-08-14 | 1.25% 10-Q · filed 2014-08-14 | ||
| 2012-12-31 | 0.94% 10-K · filed 2014-03-28 | |||
| 2012-09-30 | 1.57% 10-Q · filed 2013-11-14 | 0.94% 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | 0.93% 10-Q · filed 2013-08-14 | 0.93% 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |